维得利珠单抗治疗慢性储袋炎患者的黏膜愈合:EARNEST随机双盲安慰剂对照试验
EARNEST随机双盲安慰剂对照试验评估维得利珠单抗对慢性储袋炎成人患者的黏膜愈合及临床改善的关联。维得利珠单抗组溃疡数目较安慰剂组显著减少,黏膜愈合率在W14为16.7% vs 2.5%,W14达到黏膜愈合者W14和W34的储袋炎疾病活动指数及炎症性肠病问卷缓解率更高。
要点
- 维得利珠单抗组W14溃疡数较基线下降,且与安慰剂组差异有统计学意义。
- W14黏膜愈合率维得利珠单抗组16.7% vs 安慰剂组2.5%,差异14.2个百分点。
- W14达到黏膜愈合者W14和W34的临床及生活质量缓解率高于未达到者。
核心结论
- 维得利珠单抗使慢性储袋炎患者获得内镜下改善,且与W34结局改善相关,尤其在W14达到黏膜愈合的患者中。
研究设计与样本
- EARNEST为随机双盲安慰剂对照研究,评估维得利珠单抗在慢性储袋炎成人患者中的疗效与安全性。
- 基线、第14周和第34周进行中心判读的内镜和组织学评估。
主要发现
- 维得利珠单抗组平均溃疡数从15.1(16.4)降至W14的5.0(4.9)和W34的2.7(3.2),安慰剂组对应值为11.8(11.3)、13.4(18.4)和9.7(13.8)。
- 维得利珠单抗 vs 安慰剂溃疡数差值(95%CI):W14为-8.4(-14.3,-2.6),W34为-7.0(-12.0,-2.0)。
- 溃疡面积减少率:W14维得利珠单抗组52.4% vs 安慰剂组20.0%,差值32.4个百分点(9.7,51.4);W34为52.1% vs 12.9%,差值40.2个百分点(15.6,60.3)。
- 无溃疡率:W14维得利珠单抗组23.8% vs 安慰剂组7.5%,差值16.3个百分点(1.1,31.6);W34为34.4% vs 15.6%,差值18.8个百分点(-2.0,39.5)。
- 储袋炎疾病活动指数组织学成分 remission 和黏膜愈合率:W14黏膜愈合维得利珠单抗组16.7% vs 安慰剂组2.5%,差值14.2个百分点(1.9,26.4)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements. METHODS: EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histologic evaluation was performed at baseline, Week (W)14, and W34. Ulcer count, adapted Simple Endoscopic Score for Crohn's Disease in the pouch, and Pouchitis Disease Activity Index histologic component were evaluated. Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 were compared by MH status at W14. RESULTS: Following treatment, mean (standard deviation) number of ulcers in vedolizumab-treated patients reduced from 15.1 (16.4) to 5.0 (4.9) at W14 and 2.7 (3.2) at W34 versus placebo-treated patients with corresponding values of 11.8 (11.3), 13.4 (18.4), and 9.7 (13.8) (vedolizumab vs placebo difference [95% confidence interval]: W14: -8.4 [-14.3, -2.6]; W34: -7.0 [-12.0, -2.0]). More patients receiving vedolizumab versus placebo achieved reduction in ulcerated pouch surface area (W14: 52.4% vs 20.0%; difference, 32.4 percentage points [p.p] [9.7, 51.4]; W34: 52.1% vs 12.9%; difference, 40.2p.p [15.6, 60.3]), absence of ulceration (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), Simple Endoscopic Score for Crohn's Disease remission (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), and MH (W14: 16.7% vs 2.5%; difference, 14.2p.p [1.9, 26.4]). Patients with MH at W14 had higher rates of Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 than those without. CONCLUSIONS: Vedolizumab induced endoscopic improvements in patients with chronic pouchitis, which was associated with improved outcomes at W34, particularly in patients achieving MH at W14. (ClinicalTrials.gov number, NCT02790138.).
引用
- Jairath V, Feagan BG, Silverberg MS, et al. Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2024. PMID: 39025255. doi:10.1016/j.cgh.2024.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。